Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Harvard Gets Down To Business With $50 Million For Biomedical Accelerator, MBA Program

This article was originally published in The Pink Sheet Daily

Executive Summary

The university is setting up an evergreen translational research fund and a post-grad fellowship for the Harvard Business School with a donation from the foundation of Russian-born billionaire Len Blavatnik. The idea is to provide the financing and the business acumen to help life science research bridge the oft-noted valley of death.

You may also be interested in...

With Academic Funding, GSK Looks to Zap Life Into Electroceuticals

By seeding exploratory lab work across several biomedical and engineering disciplines, GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.

Innovation, Prevention And Technology Transfer - China Releases Five-Year Plan For Medical Technology

Likely winners include new drug, medical device and traditional Chinese medicine manufacturers, according to analysts.

Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind

While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts